98%
921
2 minutes
20
Purpose: For patients with bladder cancer (BC) undergoing radical cystectomy followed by adjuvant chemotherapy, the impact of visceral adipose tissue on prognosis and chemotherapy-related toxicities has not been well established.
Materials And Methods: From July 2013 to November 2020, 224 BC patients received adjuvant gemcitabine plus cisplatin at our institution. Computed tomography images of the patients were analyzed to calculate the visceral adipose tissue index (VATI). Patients were stratified into high- and low-VATI groups based on a predetermined cutoff value, and differences in prognosis and chemotherapy-related adverse events (AEs) between the two groups were compared.
Results: After propensity score matching, a total of 166 patients were enrolled, with 83 in the low-VATI group and 83 in the high-VATI group. The low-VATI group exhibited notably extended progression-free survival (PFS) in comparison to the high-VATI group (p = 0.044). Conversely, no substantial variation was noted concerning overall survival (OS) among the patient cohorts. In the multivariable Cox regression analysis, patients aged over 70 years (HR = 1.66, 95% CI 1.09-2.57, p = 0.04) and nodal positivity (HR = 2.98, 95% CI 1.04-4.28, p = 0.01) emerged as significant risk factors for OS. In addition to the level of VATI (HR = 2.47, 95% CI 1.02-4.21, p = 0.04), nodal positivity (HR = 4.04, 95% CI 1.30-12.56, p = 0.02) remained a significant risk factor for PFS. Regarding chemotherapy-related AEs, the most common AEs of any grade and grade ≥ 3 were hematologic toxicities. Patients in the low-VATI group exhibited a higher likelihood of experiencing grade ≥ 3 neutropenia compared to those in the high-VATI group (p = 0.04).
Conclusions: This study demonstrated that, among patients treated with adjuvant chemotherapy for locally advanced BC, patients in the low-VATI group exhibited a significantly prolonged PFS compared to those in the high-VATI group. However, no significant difference was observed in terms of OS. Regarding chemotherapy-related AEs, patients in the high-VATI group exhibited a relatively lower incidence and severity of toxic reactions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11947749 | PMC |
http://dx.doi.org/10.1002/cam4.70742 | DOI Listing |
Hepatol Res
July 2025
Department of Gastroenterology/Internal Medicine, Gifu University Graduate School of Medicine, Gifu, Japan.
Aim: We investigated the effect of body composition, including skeletal muscle index (SMI) and visceral and subcutaneous adipose tissue indices (VATI and SATI, respectively), on recurrence-free survival (RFS) and overall survival (OS) of patients with metabolic dysfunction-associated steatotic liver disease (MASLD)-associated hepatocellular carcinoma (HCC).
Methods: This study included 67 patients with MASLD-associated HCC who received curative treatment. The Cox proportional hazards model was used to evaluate whether body composition (SMI, SATI, and VATI), albumin-bilirubin score, alpha-fetoprotein level, and protein induced by vitamin K absence or antagonist-II (PIVKA-II) score were associated with RFS and OS.
Eur J Prev Cardiol
July 2025
Deutsches Herzzentrum der Charité, Hindenburgdamm 30, 12203 Berlin, Germany.
Background: While obesity is a well-established risk factor for cardiovascular disease, the relationship between visceral obesity, as assessed by imaging modalities of visceral adipose tissue (VAT), and the risk of atherosclerotic cardiovascular disease (ASCVD) has been insufficiently explored in large-scale studies, particularly across different body mass index (BMI) categories.
Aim: We aimed at investigating the association between VAT and aortic distensibility as well as risk of ASCVD and comparing the magnitude of VAT-aortic distensibility and VAT-ASCVD association across BMI groups.
Methods: Leveraging data from the UK Biobank, we examined the association between body weight-normalized VAT (VAT-index, VATi), assessed via abdominal MRI (VATi-MRI) or dual-energy X-ray absorptiometry (DXA; VATi-DXA), and aortic distensibility (a direct local measure of aortic stiffness) as well as the risk of atherosclerotic cardiovascular disease (ASCVD) over a median follow-up period of 4.
Cancer Med
April 2025
Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
Purpose: For patients with bladder cancer (BC) undergoing radical cystectomy followed by adjuvant chemotherapy, the impact of visceral adipose tissue on prognosis and chemotherapy-related toxicities has not been well established.
Materials And Methods: From July 2013 to November 2020, 224 BC patients received adjuvant gemcitabine plus cisplatin at our institution. Computed tomography images of the patients were analyzed to calculate the visceral adipose tissue index (VATI).
J Geriatr Oncol
March 2025
Department of Radiology, Tampere University Hospital, Kuntokatu 2, 33520 Tampere, Finland; Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön Katu 34, 33520 Tampere, Finland; Institute of Clinical Medicine, School of Medicine, University of Eastern Finland, Kuopio, Finland. E
Introduction: Treatment decisions are challenging in older adults with solid tumors. Geriatric 8 (G8)-screening and comprehensive geriatric assessment (CGA) are important but additional methods are needed. We examined the association of computed tomography (CT)-derived high visceral adipose tissue index (VATI) with or without low skeletal muscle index (SMI) on three-month and overall survival (OS).
View Article and Find Full Text PDFAm J Cardiol
November 2023
Kaufman Center for Heart Failure Treatment and Recovery, Heart Vascular and Thoracic Institute. Electronic address:
Obesity is a predictor of the development of systolic and diastolic heart failure (HF), but once established, patients with HF and obesity have better outcomes than their leaner counterparts, a phenomenon termed the "obesity paradox." We sought to investigate the impact of adipose tissue quantity and distribution, measured by way of computed tomography, on outcomes in patients with HF. Patients admitted for acute decompensated HF between January 2017 to December 2018 were retrospectively analyzed.
View Article and Find Full Text PDF